#	Pagina
attuale pagina	/open-h2020/projects/223439/index.html
-1	/open-h2020/per-topic/spark/list/index.html
-2	/open-h2020/projects/196540/index.html
-3	/open-h2020/projects/226113/index.html
-4	/open-h2020/projects/216018/index.html
-5	/open-h2020/projects/194233/deliverables.html

Opendata, web and dolomites

iLCA SIGNED

Intelligent Live Cell Analysis [iLCA] to transform disease management through faster, and more regulatory robust, discovery, manufacture and monitoring of biologic drugs & cell therapies

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

iLCA project word cloud

Explore the words cloud of the iLCA project. It provides you a very rough idea of what is the project "iLCA" about.

relatively entire market cell transformative image workflow recording ultimately aggressively quality made competitor therapies workflows cycle discovery diverse documentation multiple diagnostics therapy ex select last crude ideally cells ing globally preparation of manufactured regulatory drug dramatic automation requirement intense decades single size imaging forefront expensive speed entry attracting disease medicines external competition markets behalf drugs line human continued themselves patients companies life time commercial manufacturing attributes cheaper critical fundraising consuming factories global fti diagnostic gene faster editing suited shed validation provides master biologic marketed antibody platform sme innovation banks complete vivo live engineering cld penetration potentially

Project "iLCA" data sheet

The following table provides information about the project.

Coordinator	VALITACELL LTD Organization address address: FOSTERS AVE. - MOUNT MERRION, BLACKROCK city: DUBLIN 2 postcode: V94 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Ireland [IE]
Project website	https://www.valitacell.com/fti-ilca
Total cost	3˙483˙633 €
EC max contribution	2˙438˙543 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-EIC-FTI-2018-2020
Funding Scheme	IA
Starting year	2019
Duration (year-month-day)	from 2019-06-01 to 2021-05-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	VALITACELL LTD VALITACELL LTD Organization address address: FOSTERS AVE. - MOUNT MERRION, BLACKROCK city: DUBLIN 2 postcode: V94 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IE (DUBLIN 2)	coordinator	1˙135˙667.00
2	SOLENTIM LTD SOLENTIM LTD Organization address address: SOLENT HOUSE 3 JOHNSON ROAD FERNSID city: WIMBORNE postcode: BH21 7SE website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (WIMBORNE)	participant	708˙421.00
3	MICROCOAT BIOTECHNOLOGIE GMBH MICROCOAT BIOTECHNOLOGIE GMBH Organization address address: AM NEULAND 3 city: BERNRIED postcode: 82347 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (BERNRIED)	participant	594˙454.00

Map

Project objective

The detailed analysis of live cells, as shed elements of a human disease process, cell therapies themselves or as factories for the production of biologic drugs, is attracting intense focus globally from diverse companies in automation, imaging, diagnostics and manufacturing. This proposal is made on behalf of a consortium of 3 European SME’s to support the validation and preparation for commercial take-up of the market entry application, Cell Line Development [CLD], of a new transformative technology at the forefront of these areas and is ideally suited for cell line development, antibody discovery, gene editing, cell therapy, antibody engineering and ex-vivo diagnostic workflows. Each workflow provides a dramatic increase in insight, control, speed and cost, ultimately resulting in faster, cheaper and more regulatory robust medicines for European patients. Biologic drugs are large in size and are manufactured from a single cell selected following an expensive, relatively crude and time consuming process - Cell Line Development. Our technology can select the 'Top' cell using a detailed analysis of the critical quality attributes along with providing complete image recording and documentation of the growth from a single cell [regulatory requirement]. This cell selection and control is essential as all resulting master and working cell banks are used over the entire lifeâ€cycle of the marketed product that can last multiple decades. This FTI funding will enable market entry and validation & support external fundraising for the wider penetration of the global drug discovery, Cell therapy & ex-vivo diagnostic markets. This is a potentially transformative technology platform in a very large market with 1 current aggressively funded US competitor and our success will ensure competition, continued innovation and most importantly cheaper medicines for European patients.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ILCA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ILCA" are provided by the European Opendata Portal: CORDIS opendata.